This clinical trial is focused on studying a condition called Essential Thrombocythemia, which is a type of blood disorder where the body produces too many platelets. Platelets are small blood cells that help with clotting, and having too many can lead to problems like blood clots or bleeding. The study is comparing two treatments: Bomedemstat, also known by its code name MK-3543, and Hydroxycarbamide, which is also known as Hydroxyurea. These medications are being tested to see how effective and safe they are for people who have not received any previous treatment to reduce their platelet count.

The purpose of the study is to compare the effectiveness of Bomedemstat to Hydroxycarbamide in managing Essential Thrombocythemia. Participants in the study will be randomly assigned to receive either Bomedemstat, Hydroxycarbamide, or a placebo. The study will last for a period of up to 36 months, during which participants will take the medication orally in the form of capsules. Throughout the study, participants will be monitored regularly to assess their response to the treatment and to check for any side effects.

This trial aims to provide valuable information on which treatment might be more beneficial for managing Essential Thrombocythemia. By participating, individuals contribute to research that could improve future treatment options for this condition. The study is designed to ensure the safety and well-being of all participants, with regular check-ups and assessments conducted by healthcare professionals.